Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Cover Caption

About the cover: DAT TM3 electrostatic potential models. A, dot surface displays of electrostatic potentials in WT (left) and F154A (right) TM3 helices. Each TM3 was built as an -helix and energy-minimized. The 21 amino acids of TM3 cross the plasma membrane from the lower (N-terminal, cytoplasmic) side to the upper (C-terminal, extracellular) side. F154A is indicated by arrows. Dot surfaces were displayed using Sybyl 6.6 "vdW Dot Surface" with red indicating electrostatic potential measures of "V" > 24.9; orange, yellow or green 3.3 > V > 0, cyan 0 > V > 3.3 and blue, purple or white V < 24.9. "V" is defined as described previously [Weiner PA, Langridge R, Blaney JM, Scharfer R, and Kollman PK (1982) Electrostatic potential molecular surfaces. Proc Natl Acad Sci USA 79:3754-3758] at an arbitrary distance of 1.4 Å. At the helical side important for cocaine binding, there are seven residues; three (42%) are decreased and another three increased in electrostatic potentials. At the side for dopamine uptake, there are eight residues; seven of them (87%) are decreased and none of them is increased in electrostatic potentials. Indicated are amino acid residues visible on this graph to the reader and whose electrostatic potentials are reduced by the F154A substitution. Italic lables denote residues hiding from the reader (located at the opposite side of the domain). #, increased electrostatic potentials for asparagine 157 (above the arrow) and phenylalanine 150 (below the arrow). Scale bar, 5 Å. Mol Pharmacol 61:885–981.

Back to top
PreviousNext

In this issue

Molecular Pharmacology: 62 (2)
Molecular Pharmacology
Vol. 62, Issue 2
1 Aug 2002
  • Table of Contents
  • About the Cover
  • Index by author
Sign up for alerts

Jump to

  • MINIREVIEW
  • Perspective
  • Articles
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics